Australia's most trusted
source of pharma news
Friday, 23 January 2026
Posted 23 January 2026 AM
New Zealanders will soon have access to the 'Vanza Triple' after Vertex reached a provisional funding deal with Pharmac.
The agreement will see Alyftrek funded for the first time to treat cystic fibrosis (CF), with two other Vertex medicines for CF, Trikafta and Kalydeco, seeing their populations expand to all people with eligible mutations, and some new presentations.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.